Mobile website
Archive > Volume 32 Issue 11 > 2025,32(11):1169-1174. DOI:10.3872/j.issn.1007-385X.2025.11.009 Prev Next
Clinical Research
Efficacy and safety of albumin-binding paclitaxel combined with PD-1 inhibitors in the treatment of bone and soft tissue sarcoma after first-line therapy failure
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To investigate the efficacy and safety of albumin-binding paclitaxel combined with PD-1 inhibitor in the treatment of bone and soft tissue sarcomas after first-line chemotherapy failure. Methods: This retrospective study analyzed patients with advanced bone and soft tissue sarcomas who failed first-line chemotherapy and were treated at the Department of Orthopedic Oncology of Beijing Jishuitan Hospital between August 2017 and August 2020. Patients received combined treatment with albumin binding paclitaxel (125-140 mg/m2 on days 1 and 8) and anti-PD-1 therapy (sintilimab or toripalimab, every 21 days). Efficacy was evaluated every two treatment cycles according to the RECIST 1.1 criteria and adverse reactions were assessed using the NCI-CTC5.0 criteria. Results: A total of 20 patients who completed between 1 to 8 cycles of treatment with a median of 3 cycles were included in the study. All patients were evaluable for responses: 4 patients (20%) achieved complete remission; no partial remissions were observed; 9 patients (45%) had stable disease, and 7 patients (35%) had disease progression. The overall response rate (ORR) was 20%, and the disease control rate (DCR) was 65%. The median progression-free survival (PFS) was 3.0 months. The main adverse reactions during treatment included Grade 2 leukopenia (40%), Grade 1-2 neurotoxicity (20%), and Grade 2 hypothyroidism (10.0%). Conclusion: The combination therapy of albumin-binding paclitaxel and PD-1 inhibitor offers a potential treatment option for patients with advanced bone and soft tissue sarcomas who have failed first-line chemotherapy. The adverse reactions are manageable, and this regimen merits prospective studies with larger samples to further verify its efficacy.
Keywords:
Project Supported:
Clc Number:
